Drugs / Adbrelimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07645222 | Jun 2026 → Oct 2028 expected | lung cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adbrelimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07645222 ↗ |